243PMeta-analysis on association of pathological complete response with long-term survival outcomes in triple-negative breast cancer

ConclusionsThis study confirms the strong association between pCR and survival outcomes in TNBC based on evidence synthesis from both clinical and real-world settings. In addition, this study suggests potential survival benefit of subsequent adjuvant therapy for TNBC patients who received neoadjuvant therapy.Legal entity responsible for the studyMerck& Co., Inc.FundingMerck& Co., Inc.DisclosureP.A. Fasching: Advisory / Consultancy: Merck& Co., Inc. M. Huang: Full / Part-time employment: Merck& Co., Inc. J. Cort és: Advisory / Consultancy: Merck& Co., Inc. J. Zhao: Full / Part-time employment: Merck& Co., Inc. J. O ’Shaughnessy: Advisory / Consultancy: Merck& Co., Inc. P. Hu: Full / Part-time employment: Merck& Co., Inc. A. Haiderali: Full / Part-time employment: Merck& CO., Inc. V. Karantza: Full / Part-time employment: Merck& Co., Inc. G. Aktan: Full / Part-time employment: Merck& Co., Inc. A. Briggs: Advisory / Consultancy: Merck& Co., Inc. S. Ramsey: Advisory / Consultancy: Merck& Co., Inc. C.Z. Qi: Advisory / Consultancy, Employee of Analysis Group, Inc., which has received consulting fees from Merck& Co., Inc.: Merck& Co., Inc. J. Xie: Advisory / Consultancy, Employee of Analysis Group, Inc., which has received consulting fees from Merck& Co., Inc.: Merck& Co., Inc. C. Gu: Advisory / Consultancy, Employee of Analysis Group, Inc., which has received consulting fees from Merck& Co., Inc.: Merck&...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research